B.Braun's plans after acquiring Timisoara intravenous infusion fluid plant

Arrived in Bucharest to announce 6m-euro investments in 2010 and 2011, as well as the acquisition of Helvetica Profarm intravenous infusion fluid plant, Christian Braun, CEO of B. Braun Central & Eastern Europe, and shareholder in the German pharmaceutical and medical device giant with annual turnover of around 4bn euros, lays out development plans for the following period. He starts by saying the Romanian market is "highly promising" and then adds that part of Timisoara production will go abroad. The 6m-euro investments will be aimed at boosting production capacity by 7 million units, from 12 million at present. In late 2010, Helvetica Profarm will be renamed as B. Braun Pharmaceutics SA, after the name of old products is changed. Without the plant, B. Braun generated 52m RON turnover and for 2010 targets 21% growth. "As a result of the financial crisis, with an impact in Romania as well, we had weaker turnover growth last year, of 1.5%, which is not satisfying. This year we want to revert to stronger growth and reach 63m RON," said Martin Wenderoth, executive manager with B. Braun Medical SRL.